Helicobacter pylori treatment in the era of increasing antibiotic resistance

Gut

Volumn 59, Issue 8, 2010, Pages 1143-1153

  Graham, David Y ^a   Fischbach, Lori ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; HELIDAC; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITAZOXANIDE; NITROIMIDAZOLE; PLACEBO; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CARCINOGENICITY; DRUG DOSE; DRUG EFFICACY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH PH; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77954704743     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.192757     Document Type: Review

References (147)

1. Hopkins RJ. In search of the Holy Grail of Helicobacter pylori remedies. Helicobacter 2001;6:81-3.
2. Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009;14:86-90.
3. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84. (Pubitemid 39120130)
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
5. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
6. Caselli M, Zullo A, Maconi G, et al. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-9.
7. Fischbach LA, Goodman KJ, Feldman M, et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002;31:128-39. (Pubitemid 34284915)
8. Filipec KT, Katicic M, Skurla B, et al. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009;14:29-35.
9. Fischbach LA, Bravo LE, Zarama GR, et al. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country. Helicobacter 2009;14:100-8.
10. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol 2009;256:758-67.
11. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017-24.
12. Oh JH, Dong MS, Choi MG, et al. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol 2009;24:294-8.
13. Soler JA, Guell M, Briculle M, et al. H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study. Ann Hematol 2009;88:769-73.
14. Choi WH, Park DI, Oh SJ, et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008;51:280-4.
15. Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci 2009;54:599-603.
16. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
17. Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008;23(Suppl 2):S171-4.
18. Kim CG, Song HJ, Kook MC, et al. Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. Am J Gastroenterol 2008;103:48-54.
19. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008;13:542-9.
20. Kim SY, Lee SW, Jung SW, et al. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study. Helicobacter 2008;13:282-7.
21. Kim HW, Kim GH, Cheong JY, et al. H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008;14:908-12.
22. Namiot DB, Leszczynska K, Namiot Z, et al. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv Med Sci 2008;53:310-15.
23. Rostami N, Keshtkar-Jahromi M, Rahnavardi M, et al. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol 2008;83:376-81. (Pubitemid 351614750)
24. Tzathas C, Triantafyllou K, Mallas E, et al. Effect of Helicobacter pylori eradication and antisecretory maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study. J Clin Gastroenterol 2008;42:744-9.
25. Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 2008;12:251-6.
26. Uygun A, Kadayifci A, Yesilova Z, et al. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther 2008;30:528-34. (Pubitemid 351483928)
27. de Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007;12:477-85.
28. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31-5.
29. Wu IC, Wu DC, Hsu PI, et al. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection. Helicobacter 2007;12:633-7.
30. Subei IM, Cardona HJ, Bachelet E, et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in Helicobacter pylori-positive patients. Dig Dis Sci 2007;52:1505-12. (Pubitemid 46776496)
31. Shmuely H, Yahav J, Samra Z, et al. Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor. Mol Nutr Food Res 2007;51:746-51. (Pubitemid 47083685)
32. Riquelme A, Soza A, Pedreros C, et al. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. World J Gastroenterol 2007;13:2967-72.
33. Nagahara A, Miwa H, Hojo M, et al. Efficacy of Lansap combination therapy for eradication of H. pylori. Helicobacter 2007;12:643-4.
34. Magen E, Mishal J, Schlesinger M, et al. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter 2007;12:567-71. (Pubitemid 47312386)
35. Itatsu T, Miwa H, Nagahara A, et al. Eradication of Helicobacter pylori in hemodialysis patients. Ren Fail 2007;29:97-102.
36. Hong L, Zhao Y, Han Y, et al. Reversal of migraine symptoms by Helicobacter pylori eradication therapy in patients with hepatitis-B-related liver cirrhosis. Helicobacter 2007;12:306-8. (Pubitemid 47196337)
37. Hagiwara T, Kato M, Anbo T, et al. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. World J Gastroenterol 2007;13:3836-40.
38. Garza GE, Giasi GE, Martinez Vazquez MA, et al. Helicobacter pylori eradication and its relation to antibiotic resistance and CYP2C19 status. Rev Esp Enferm Dig 2007;99:71-5.
39. Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007;12:309-16. (Pubitemid 47196340)
40. Choi HS, Park DI, Hwang SJ, et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007;12:638-42.
41. Bago P, Vcev A, Tomic M, et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007;119:372-8. (Pubitemid 47087507)
42. Zullo A, Perna F, Ricci C, et al. 13C-urea breath test values and Helicobacter pylori eradication. Dig Dis Sci 2008;53:370-4. (Pubitemid 351170033)
43. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007;12:317-23. (Pubitemid 47196333)
44. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
45. Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007;56:475-9. (Pubitemid 46580501)
46. Maconi G, Tosetti C, Miroglio G, et al. Management of Helicobacter pylori-related gastrointestinal diseases by general practitioners in Italy. Aliment Pharmacol Ther 1999;13:1499-504. (Pubitemid 29516263)
47. de Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100. (Pubitemid 46768227)
48. Higuchi K, Maekawa T, Nakagawa K, et al. Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. Clin Drug Investig 2006;26:403-14.
49. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006;11:418-24.
50. Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2006;21:262-7.
51. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006;101:1985-90.
52. Scaccianoce G, Hassan C, Panarese A, et al. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006;20:113-17.
53. Sugimoto M, Furuta T, Shirai N, et al. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin Pharmacol Ther 2006;80:41-50. (Pubitemid 43946842)
54. Wu DC, Hsu PI, Chen A, et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006;36:803-9.
55. Zhang L, Shen L, Ma JL, et al. Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. World J Gastroenterol 2006;12:3915-18.
56. Ziemniak W. Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol 2006;57(Suppl 3):123-41. (Pubitemid 44641541)
57. Calvet X, Ducons J, Bujanda L, et al. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005;100:1696-701. (Pubitemid 41648420)
58. Crispino P, Iacopini F, Pica R, et al. Beta-lactamase inhibition with clavulanic acid supplementing standard amoxycillin-based triple therapy does not increase Helicobacter pylori eradication rate. Dig Liver Dis 2005;37:826-31. (Pubitemid 44356111)
59. Furuta T, Shirai N, Xiao F, et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2004;2:22-30. (Pubitemid 38165396)
60. Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol 2005;3:564-73.
61. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100:2387-92.
62. Park SH, Park DI, Kim SH, et al. Effect of high-dose aspirin on Helicobacter pylori eradication. Dig Dis Sci 2005;50:626-9.
63. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005;21:1419-24.
64. Altintas E, Sezgin O, Ulu O, et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004;10:1656-8. (Pubitemid 38786950)
65. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004;19:407-14.
66. Ghazzawi IM, Obeidat WA, Zuriekat FA. Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers. Saudi Med J 2004;25:1006-9.
67. He XX, Zhao YH, Hao YT. Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese. Zhonghua Nei Ke Za Zhi 2004;43:13-15.
68. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107. (Pubitemid 38938723)
69. Take S, Mizuno M, Ishiki K, et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol 2003;98:2403-8.
70. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
71. Della Monica P, Lavagna A, Masoero G, et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-75.
72. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002;16:1933-8.
73. Nagahara A, Miwa H, Yamada T, et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:417-21. (Pubitemid 32187564)
74. Catalano F, Branciforte G, Catanzaro R, et al. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther 2000;14:1329-34.
75. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000;5:88-93. (Pubitemid 34948013)
76. Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501. (Pubitemid 29176873)
77. Laine L, Frantz JE, Baker A, et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 1997;11:913-17.
78. Lai YC, Yang JC, Huang SH. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol 2004;10:991-4.
79. Bhatia V, Ahuja V, Das B, et al. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J Gastroenterol Hepatol 2004;19:619-25. (Pubitemid 38858192)
80. Bago J, Galovic A, Belosic HZ, et al. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr 2004;116:495-9. (Pubitemid 39178310)
81. Anagnostopoulos GK, Tsiakos S, Margantinis G, et al. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004;38:503-6. (Pubitemid 38808423)
82. Schaeverbeke T, Broutet N, Zerbib F, et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. Am J Gastroenterol 2005;100:2637-43.
83. Ruiz GA, Gordillo Lopez FJ, Hermosa Hernan JC, et al. Effect of the Helicobacter pylori eradication in patients with functional dyspepsia: randomised placebo-controlled trial. Med Clin (Barc) 2005;124:401-5.
84. Feng LY, Yao XX, Jiang SL. Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. World J Gastroenterol 2005;11:1083-6.
85. Sancar M, Izzettin FV, Apikoglu-Rabus S, et al. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. Pharm World Sci 2006;28:207-14. (Pubitemid 44673749)
86. Mirbagheri SA, Hasibi M, Abouzari M, et al. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. World J Gastroenterol 2006;12:4888-91. (Pubitemid 44323218)
87. Madisch A, Miehlke S, Neuber F, et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy - a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006;23:473-9.
88. Ang TL, Fock KM, Teo EK, et al. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. J Gastroenterol 2006;41:647-53.
89. Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003;8:626-42.
90. Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998;158:1651-6. (Pubitemid 28371188)
91. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8. (Pubitemid 47196342)
92. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti- Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82. (Pubitemid 39657940)
93. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
94. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57. (Pubitemid 47063149)
95. Bardhan K, Bayerdorffer E, Veldhuyzen van Zanten SJ, et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000;5:196-201.
96. van der Hulst RWM, Keller JJ, Rauws EA, et al. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996;1:6-19. (Pubitemid 126671070)
97. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53
98. Megraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
99. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1:138-44.
100. Schwartz H, Krause R, Sahba B, et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998;93:584-90. (Pubitemid 29081007)
101. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11(Suppl 1):27-33.
102. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322. (Pubitemid 46709306)
103. Dore MP, Osato MS, Realdi G, et al. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother 1999;43:47-54.
104. Raymond J, Larmaque D, Kalach N, et al. High level antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010;15:21-7.
105. Occhialini A, Urdaci M, Doucet-Populaire F, et al. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997;41:2724-8. (Pubitemid 27524747)
106. Giannini EG, Bilardi C, Dulbecco P, et al. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol 2006;40:515-20. (Pubitemid 44318136)
107. Keren I, Kaldalu N, Spoering A, et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004;230:13-18.
108. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007;5:48-56. (Pubitemid 44942303)
109. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007;4:e120.
110. Tanimura H, Kawano S, Kubo M, et al. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J Gastroenterol 1998;33:23-6. (Pubitemid 28067770)
111. Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 1944;247:497-500.
112. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:331.
113. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995;30:401-7.
114. Dubois A, Boren T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol 2007;9:1108-16. (Pubitemid 46547131)
115. Necchi V, Candusso ME, Tava F, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology 2007;132:1009-23. (Pubitemid 46440875)
116. Ito T, Kobayashi D, Uchida K, et al. Helicobacter pylori invades the gastric mucosa and translocates to the gastric lymph nodes. Lab Invest 2008;88:664-81.
117. Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut 1998;43(Suppl 1):S56-60.
118. Scott DR, Marcus EA, Wen Y, et al. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci USA 2007;104:7235-40. (Pubitemid 47186038)
119. Gotoh A, Akamatsu T, Shimizu T, et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 2002;7:183-91.
120. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341-8.
121. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
122. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd edn. New York: Springer-Verlag, 1998.
123. Graham DY, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti Helicobacter pylori therapy. Ann Intern Med 2007;147:434-5. (Pubitemid 351664552)
124. Nakamura A, Furuta T, Shirai N, et al. Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele-specific primer-polymerase chain reaction method. J Gastroenterol Hepatol 2007;22:1057-63.
125. Noguchi N, Rimbara E, Kato A, et al. Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J Med Microbiol 2007;56:1174-80. (Pubitemid 47477188)
126. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-8.
127. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
128. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998;33:640-5. (Pubitemid 28464258)
129. Treiber G, Ammon S, Schneider E, et al. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998;3:54-8. (Pubitemid 128656411)
130. Okada M, Nishimura H, Kawashima M, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 1999;13:769-74. (Pubitemid 29276846)
131. Treiber G, Wittig J, Ammon S, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60. (Pubitemid 34098184)
132. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41.
133. Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:715-18. (Pubitemid 30352737)
134. De Francesco V, Zullo A, Hassan C, et al. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Dig Liver Dis 2001;33:676-9. (Pubitemid 33107667)
135. Hassan C, De Francesco V, Zullo A, et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 2003;18:641-6. (Pubitemid 37186614)
136. De Francesco V, Della VN, Stoppino V, et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2004;19:993-8. (Pubitemid 38657380)
137. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004;36:322-6.
138. Sanchez-Delgado J, Calvet X, Bujanda L, et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008;103:2220-3.
139. Ueki N, Miyake K, Kusunoki M, et al. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter 2009;14:91-9.
140. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008;68:725-36. (Pubitemid 351550527)
141. George LL, Borody TJ, Andrews P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990;153:145-9. (Pubitemid 20244927)
142. de Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995;345:817-20.
143. de Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:697-700.
144. Glupczunski Y, Bourdeaux L, De Prez C, et al. Prevalence of Helicobacter pylori in rural Kivu, eastern Zaire: a prospective endoscopic study. Eur J Gastroenterol Hepatol 1991;3:449-55.
145. Hung IF, Chan P, Leung S, et al. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 2009;14:505-11.
146. Kim JM, Kim JS, Kim N, et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-7. (Pubitemid 41631929)
147. Graham DY, Abudayyeh S, El-Zimaity HM, et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006;24:845-50.